This trial is studying how well different treatment regimens work in treating patients with serous or p53 abnormal endometrial cancer.
1 Primary · 2 Secondary · Reporting Duration: 5 years
Active Control
Experimental Treatment
120 Total Participants · 5 Treatment Groups
Primary Treatment: Carboplatin · No Placebo Group · Phase 2 & 3
Age 18+ · Female Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: